Brainstorm Cell Therapeutics (BCLI) Reports Q2 Loss of $0.16/Share
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.16), versus ($0.06) reported last year.
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
- XP Inc eyes US banking license as next business step
- INVO Fertility (IVF) Tops Q2 EPS by 105c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
